671 related articles for article (PubMed ID: 11515848)
1. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
2. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
Kam L; Cohen H; Dooley C; Rubin P; Orchard J
Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
[TBL] [Abstract][Full Text] [Related]
3. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
4. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
Fukuda T; Naganuma M; Takabayashi K; Hagihara Y; Tanemoto S; Nomura E; Yoshimatsu Y; Sugimoto S; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Mutaguchi M; Inoue N; Ogata H; Iwao Y; Abe T; Kanai T
J Gastroenterol Hepatol; 2020 Nov; 35(11):1878-1885. PubMed ID: 32250471
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
Li J; Chen C; Cao XN; Wang GH; Hu JB; Wang J
J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):59-65. PubMed ID: 24496680
[TBL] [Abstract][Full Text] [Related]
6. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.
Frieri G; Giacomelli R; Pimpo M; Palumbo G; Passacantando A; Pantaleoni G; Caprilli R
Gut; 2000 Sep; 47(3):410-4. PubMed ID: 10940280
[TBL] [Abstract][Full Text] [Related]
7. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
Cohen HD; Das KM
J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
[TBL] [Abstract][Full Text] [Related]
8. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
9. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Harris MS; Lichtenstein GR
Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
[TBL] [Abstract][Full Text] [Related]
10. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
[TBL] [Abstract][Full Text] [Related]
11. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
D'Incà R; Paccagnella M; Cardin R; Pathak S; Baldo V; Giron MC; Sturniolo GC
World J Gastroenterol; 2013 Sep; 19(34):5665-70. PubMed ID: 24039359
[TBL] [Abstract][Full Text] [Related]
12. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis.
Yamamoto Y; Masuda S; Nakase H; Matsuura M; Maruyama S; Hisamatsu T; Suzuki Y; Matsubara K
Biol Pharm Bull; 2019 Jan; 42(1):81-86. PubMed ID: 30369547
[TBL] [Abstract][Full Text] [Related]
13. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Sutherland L; Macdonald JK
Cochrane Database Syst Rev; 2006 Apr; (2):CD000543. PubMed ID: 16625536
[TBL] [Abstract][Full Text] [Related]
14. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
Marshall JK; Irvine EJ
Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
[TBL] [Abstract][Full Text] [Related]
15. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Sutherland L; Macdonald JK
Cochrane Database Syst Rev; 2006 Apr; (2):CD000544. PubMed ID: 16625537
[TBL] [Abstract][Full Text] [Related]
16. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Sutherland L; Roth D; Beck P; May G; Makiyama K
Cochrane Database Syst Rev; 2002; (4):CD000544. PubMed ID: 12519547
[TBL] [Abstract][Full Text] [Related]
17. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
Kao J; Kwok K; Das KM
J Clin Gastroenterol; 2010 Sep; 44(8):531-5. PubMed ID: 20495466
[TBL] [Abstract][Full Text] [Related]
18. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
19. The role of aminosalicylates in the treatment of ulcerative colitis.
Van Assche G; Baert F; De Reuck M; De Vos M; De Wit O; Hoang P; Louis E; Mana F; Pelckmans P; Rutgeerts P; Van Gossum A; D'Haens G
Acta Gastroenterol Belg; 2002; 65(4):196-9. PubMed ID: 12619425
[TBL] [Abstract][Full Text] [Related]
20. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
